Immunotherapy tested against tough brain tumors that keep coming back
NCT ID NCT03279692
Summary
This study tested whether the immunotherapy drug pembrolizumab could help control aggressive brain tumors called high-grade meningiomas that have returned or persisted after previous treatments. The trial involved 26 adults whose tumors showed signs of progression. Researchers monitored whether the treatment could stop tumor growth for at least six months while tracking side effects and survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.